The Glutamic Acid-rich Protein-2 (GARP2) Is a High Affinity Rod Photoreceptor Phosphodiesterase (PDE6)-binding Protein That Modulates Its Catalytic Properties*

Dana C. Pentia, Suzanne Hosier, and Rick H. Cote 1
From the Department of Biochemistry and Molecular Biology, University of New Hampshire, Durham, New Hampshire 03824-2617

The glutamic acid-rich protein-2 (GARP2) is a splice variant of the β-subunit of the cGMP-gated ion channel of rod photoreceptors. GARP2 is believed to interact with several membrane-associated phototransduction proteins in rod photoreceptors. In this study, we demonstrated that GARP2 is a high affinity PDE6-binding protein and that PDE6 co-purifies with GARP2 during several stages of chromatographic purification. We found that hydrophobic interaction chromatography succeeds in quantitatively separating GARP2 from the PDE6 holoenzyme. Furthermore, the 17-kDa prenyl-binding protein, abundant in retinal cells, selectively released PDE6 (but not GARP2) from rod outer segment membranes, demonstrating the specificity of the interaction between GARP2 and PDE6. Purified GARP2 was able to suppress 80% of the basal activity of the nonactivated, membrane-bound PDE6 holoenzyme at concentrations equivalent to its endogenous concentration in rod outer segment membranes. However, GARP2 was unable to reverse the transducin activation of PDE6 (in contrast to a previous study) nor did it significantly alter catalysis of the fully activated PDE6 catalytic dimer. The high binding affinity of GARP2 for PDE6 and its ability to regulate PDE6 activity in its dark-adapted state suggest a novel role for GARP2 as a regulator of spontaneous activation of rod PDE6, thereby serving to lower rod photoreceptor “dark noise” and allowing these sensory cells to operate at the single photon detection limit.

The visual transduction pathway in vertebrate photoreceptors is remarkable in many respects, including single photon detection capability (in rod photoreceptors), photoreponse kinetics on the millisecond time scale, and the ability to adapt to background illumination levels ranging from very dim illuminance levels (scotopic vision in rods) to bright sunlight (photopic vision in cones) (1). The very first steps in vision occur in the photoreceptor outer segment when photo-isomerization of rhodopsin activates the heterotrimeric G-protein transducin, which proceeds to bind to and displace the inhibitory γ-subunit (Py)2 of the photoreceptor phosphodiesterase (PDE6). Activated PDE6 rapidly lowers the cGMP concentration, resulting in closure of cGMP-gated channels in the plasma membrane and cell hyperpolarization (2–4). Several feedback mechanisms operate to actively terminate the photoreponse and restore the dark-adapted state, of which regulation of the lifetime of activated transducin is considered rate-limiting (2, 3). Rebinding of Py to the PDE6 catalytic subunits following transducin deactivation returns PDE6 to its nonactivated state and allows cGMP levels to return to their dark-adapted levels.

Electrophysiological evidence supports the hypothesis that factors in addition to transducin deactivation are involved in regulating the lifetime of light-activated PDE6 during light adaptation of rod photoreceptors (5, 6). Several potential feedback mechanisms for modulating activated PDE6 have been proposed (7–9) but have not been explored in sufficient detail to validate their relevance to the phototransduction pathway.

The catalytic activity of PDE6 in its dark-adapted state also must be tightly controlled to prevent any spontaneous activation of PDE6 that would consume metabolic energy unnecessarily and impair the ability of rod cells to reliably detect very dim flashes of light. Physiological measurements of “dark noise” reveal a component that represents spontaneous activation of PDE6 and which is much greater in magnitude in cones than in rods (10–12). Subtle differences in the highly homologous rod and cone isoforms of PDE6 might account for the different dark noise in rods and cones, although this is not evident from biochemical comparisons of purified rod and cone PDE6 (13–16). An alternative possibility is that a rod- or cone-specific PDE6-binding protein suppresses the spontaneous activation of PDE6 by enhancing the affinity of Py at the PDE6 catalytic site.

One candidate protein that might serve to regulate PDE6 in both its nonactivated and activated states is the glutamic acid-rich protein-2 (GARP2), a protein that exists in rod outer segments but is absent in cones (8, 17). GARP2 is a product of alternative splicing of the β-subunit of the rod cGMP-gated ion channel (CNGB1) and contains a unique 8-amino-acid C-terminal extension (8, 17). This 32-kDa protein is unusual in that it has a high content of proline and glutamate residues (17–19).

The functions served by GARP2 in rod outer segments are unknown. Potential binding partners for GARP2 include proteins involved in phototransduction and disk membrane structural integrity (8, 20), but the physiological significance of these interactions is unclear. In one previous study, it was reported that the addition of GARP2 to preparations of PDE6 reversed its activation by transducin, whereas GARP2 had no effect on the nonactivated PDE6 holoenzyme or on the catalytic dimer of PDE6 lacking bound Py (8). It was proposed that GARP2 down-regulation of PDE6 activation in the vicinity of the plasma membrane might conserve metabolic energy during daylight when rod function is saturated.

In this paper, we have examined the interaction of GARP2 with PDE6 and characterized the effect of GARP2 on PDE6 function. We show that

---

*This work was supported by National Institutes of Health Grant EY05798 (to R. H. C.) and is Scientific Contribution 2269 from the New Hampshire Agricultural Experiment Station. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, University of New Hampshire, 46 College Rd., Durham, NH 03824-2617. Tel.: 603-862-2458; Fax: 603-862-4013; E-mail: rick.cote@unh.edu.

2 The abbreviations used are: Py, inhibitory 10-kDa γ-subunit of PDE6; GARP, glutamic acid-rich protein; PDE6, photoreceptor phosphodiesterase; PrBP/G, 17-kDa prenyl-binding protein; GTPγS, guanosine 5′-3′-O-(thio)triphosphate; ROS, rod outer segment; HIC, hydrophobic interaction chromatography; HPLC, high pressure liquid chromatography.
GARP2 binds PDE6 with high affinity and co-purifies with the enzyme through several stages of purification. We have been unable to confirm the previously reported inhibitory effect of GARP2 on transducin-activated PDE6 (8). Instead, we observed that purified, native GARP2 has a strong effect in suppressing the basal activity of PDE6 in its nonactivated state. The implications of GARP2 modulation of basal PDE6 activity in dark-adapted rods are discussed.

**EXPERIMENTAL PROCEDURES**

*Materials*—Bovine retinas were purchased from W. L. Lawson, Inc. Chromatography supplies were purchased from G. E. Healthcare and Pierce. Supplies for immunoblotting were purchased from Schleicher & Schuell, Pierce, and Bio-Rad. Chemicals were obtained from Sigma. The bovine recombinant GST-PrBP/δ fusion protein was a gift of Dr. Richard Hurwitz (Baylor College of Medicine). The ROS1 monoclonal antibody used for immunoprecipitation was a gift of Dr. Joe Beavo (University of Washington). Rabbit polyclonal anti-GARP2 antibody to the unique C-terminal sequence of GARP2 (17) was a gift of Dr. Benjamin Kaupp (Institut für Biologische Informationsverarbeitung, Jülich, Germany). Affinity-purified anti-peptide rabbit polyclonal antibodies directed to the PDE6 GAPb domain (termed NC) and to the C terminus of the Py-subunit of PDE6 (CT-9710) were produced in our laboratory. The ROS1 monoclonal antibody used for immunoprecipitations (21) was a gift of Dr. Richard Hurwitz (Baylor College of Medicine).

ROS Membrane Isolation and Purification—ROS membranes from bovine retina were prepared as described previously (22). Briefly, ROSs were isolated from frozen bovine retinas on a discontinuous sucrose gradient. ROS membranes were homogenized in an isotonic buffer (10 mM Tris, pH 7.5, 60 mM KCl, 40 mM NaCl, 2 mM MgCl₂, 1 mM dithiothreitol, 0.3 mM phenylmethylsulfonyl fluoride) using a glass, handheld homogenizer. The soluble proteins were separated from membranes by centrifugation.

Native GARP2 Purification—GARP2 was isolated from ROS membranes and purified to homogeneity as follows. First, ROS membranes were homogenized in a hypotonic buffer (10 mM Tris, pH 7.5, 0.2 mM MgCl₂, 1 mM dithiothreitol). The soluble proteins were separated from membranes by centrifugation. ROS membranes were homogenized in an isotonic buffer (10 mM Tris, pH 7.5, 60 mM KCl, 40 mM NaCl, 2 mM MgCl₂, 1 mM dithiothreitol, 0.3 mM phenylmethylsulfonyl fluoride) using a glass, handheld homogenizer. The soluble proteins were separated from membranes by centrifugation.

PDE6 Purification—Purified PDE6 was prepared as described elsewhere (22). Briefly, a hypotonic extract of purified ROS membranes was loaded onto a Mono Q column. The proteins were eluted using a linear gradient from 100 mM NaCl to 1 M NaCl in 5 mM Tris, pH 7.5. The PDE6 peak was collected, concentrated, and further purified on a Superdex 200 gel filtration column using the following buffer: 5 mM Tris, pH 7.5, 300 mM NaCl, 1 mM dithiothreitol, and 3 mM phenylmethylsulfonyl fluoride. The gel filtration column was calibrated using the following: thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), aldolase (158 kDa), bovine serum albumin (43 kDa), ovalbumin (29 kDa), blue dextran for the void volume, and adenosine triphosphate for the included volume.

Immunoprecipitation of PDE6 with the Monoclonal Antibody ROS1—The ROS1 antibody to PDE6 (21) coupled to Sulfolink beads (Pierce) was used for immunoprecipitation of PDE6 and its binding partners. Hypotonic extracts from bovine ROS or Mono Q-purified PDE6 (containing 5–10 pmol of PDE6) were incubated for 2 h at 4 °C with 20 μl of prewashed ROS1 beads in a total volume of 100 μl. The samples were centrifuged to separate bound from unbound proteins, and the beads were washed extensively before the proteins were eluted in Laemmli sample buffer. As a control for nonspecific binding of GARP2 to the beads, purified GARP2 was also tested with the ROS1-Sulfolink beads. Portions of the starting material, bound proteins, and unbound proteins were subjected to SDS-PAGE followed by Western blotting for PDE6 (NC antibody) and GARP (chicken anti-GARP antibody).

PrBP/δ Expression and Purification—Recombinant bovine PrBP/δ was expressed in the *Escherichia coli* strain BL21 (23). Protein expression was induced by the addition of 1 mM isopropyl-β-D-thiogalactopyranoside to log phase cultures. Bacterial cells were incubated for 1 h at 37 °C, lysed by sonication, and soluble proteins were recovered following centrifugation. GST-PrBP/δ was purified on a glutathione-agarose column. GST-PrBP/δ concentration was determined by a colorimetric protein assay (24).

Protein Quantification—The amount of rhodopsin in dark-adapted ROS membranes was determined by difference spectroscopy (25). The PDE6 concentration was routinely determined by measurements of trypsin-activated PDE6 maximum activity (*V*₅₀) (26) and knowledge of the turnover number (*k*ₐₙ = 5600 cGMP/s/PDE6; [PDE6] = *V*₅₀/*k*ₐₙ) (27). Independent determinations of the ratio of rhodopsin to PDE6 in purified bovine ROS gave a value of 310 ± 20 rhodopsins per PDE6 (n = 5), very similar to the values for amphibian ROS of 270 (28) to 330 (29) rhodopsins per PDE.

The amount of purified GARP2 was routinely estimated by immunoblot analysis. Samples of purified GARP2 and known amounts of ROS membranes were resolved on SDS-PAGE and immunoblotted. GARP2 was detected using a GARP2-specific antibody. The intensities of GARP2 immunoreactive bands were determined using Quantiscan (Biosoft) and then compared with GARP2 immunoreactivity in ROS membranes containing known amounts of rhodopsin and PDE6.

**SDS-PAGE and Western Blotting—**SDS-PAGE was performed by the method of Laemmli (30) in 10, 12, or 15% acrylamide gels. The immunoblotting procedure followed the protocols in Gallagher (31). Note that GARP2 typically migrates at ~60 kDa (roughly 2-fold higher than predicted based on its amino acid sequence) and shows size heterogeneity, in accord with previous observations (8, 19). This anomalous behavior was recently explained as being due to GARP2 existing in solution as a natively unfolded protein (32).
Regulation of PDE6 by GARP2

RESULTS AND DISCUSSION

GARP2 Is a High Affinity PDE6-binding Protein—Because there is uncertainty about the proteins with which GARP2 interacts in rod photoreceptors (8, 20), we first re-examined whether PDE6 interacts in a specific manner with GARP2. Following homogenization of purified ROS from bovine retina and removal of soluble proteins with isothiocyanate washes, PDE6 and GARP2 both remained associated with ROS disk membranes (Fig. 1A). Release of PDE6 from ROS membranes by exposure to a hypotonic buffer also caused the release of almost all detectable GARP2 (Fig. 1A). Subsequent purification of PDE6 by anion-exchange chromatography on a Mono Q column resulted in co-elution of PDE6 and GARP2 at 400 mM NaCl. Gel filtration chromatography of the Mono Q-purified GARP2-PDE6 also failed to separate GARP2 from PDE6 (Fig. 1A). The results in Fig. 1A conclusively demonstrate that PDE6 and GARP2 are both associated with ROS membranes, are co-eluted by exposure to a hypotonic buffer, and co-purify by two different chromatographic procedures.

To directly show that GARP2 is associated with PDE6, we immunoprecipitated PDE6 with the ROS1 antibody (21) coupled to Sulfitolink beads. Fig. 1B shows that unpurified PDE6 obtained from hypotonic extraction of ROS membranes was pulled down in a complex with GARP2 and that very little GARP2 remained unbound under these conditions. Mono Q-purified PDE6 was also immunoprecipitated in tight association with GARP2, whereas purified GARP2 failed to bind to the ROS1 antibody in the absence of PDE6 (Fig. 1B).

To estimate whether a significant amount of the PDE6 exists free of bound GARP2, we performed gel filtration chromatography on proteins solubilized from dark-adapted ROS membranes with a hypotonic buffer. A single peak of PDE6 hydrolytic activity (Fig. 1C) and immunoreactivity (Fig. 1D) was observed at an apparent molecular mass of 330 kDa. (The higher than predicted molecular mass for the PDE6-GARP2 complex by gel filtration chromatography may be due to its asymmetric shape (14).) Qualitatively, the observed ratio of PDE6 and GARP2 immunoreactivity did not vary in the fractions containing PDE6, indicating that there is not a large fraction of the total PDE6 that exists free of bound GARP2. Further, only small amounts of GARP2 immunoreactivity could be detected at an apparent molecular mass of ∼30–60 kDa (Fig. 1D). This result indicated that PDE6 is tightly associated with GARP2 and that there is no evidence for a significant amount of unbound GARP2 or PDE6.

To assess whether GARP2 binding to PDE6 might be an artifact of the initial hypotonic extraction of ROS membrane proteins, we also solubilized PDE6 and GARP2 from dark-adapted ROS membranes with 1% Triton X-100. After removing the ROS membranes by centrifugation and immunoprecipitation of the detergent-solubilized PDE6 with the ROS1 antibody, we detected both PDE6 and GARP2 in the immunoprecipitates; control samples with beads lacking the ROS1 antibody failed to pull down either protein (data not shown). Together, these results demonstrate that most of the GARP2 in ROS co-purifies with PDE6 through several stages of purification. The fact that GARP2 remained bound to PDE6 after repeated washing of the ROS1 immuno complex (Fig. 1B) and that little unbound GARP2 was observed during gel filtration chromatography (Fig. 1D) demonstrates that GARP2 binds PDE6 with high affinity.

GARP2 Content in Rod Photoreceptors—If GARP2 is to regulate PDE6 activity during phototransduction, it would need to be present in ROS in molar equivalence to PDE6. A previous study by Kaupp and colleagues (8) suggested that GARP2 is actually ∼3-fold more abundant than PDE6 (1 GARP2 per 100 rhodopsins). Another GARP2-interacting protein, peripherin, is believed to bind only 10% of the total GARP2 in ROS (20). Our observation that practically all GARP2 in bovine ROS co-purified with PDE6 (Fig. 1) suggested that GARP2 was not significantly more abundant than PDE6 in ROS.

To directly address the question of the GARP2 content in ROS, we purified native GARP2 from bovine ROS, as described in the next section, and compared the immunoreactivity of known amounts of GARP2 to that of intact ROS whose rhodopsin and PDE6 concentration were measured. The precision of our measurements were hampered by uncertainties in the concentration of purified GARP2 used for quantitative immunoblots, because the poor staining of GARP2 by Coomassie and other protein stains limited our ability to assess its purity on SDS-PAGE (see next section). Taking this into consideration, we estimate that there are 1–2 GARP2 molecules per PDE6 holoenzyme in bovine ROS (data not shown). This value agrees well with two other reports (8,
Regulation of PDE6 by GARP2

On Coomassie-stained gels of purified GARP2, >50% of the total staining was observed at ~60 kDa, corresponding to GARP2 (Fig. 2C). No detectable protein was observed at molecular masses corresponding to PDE6 catalytic or inhibitory subunits. The GARP2 purity was likely to be much higher, because this glutamate-rich protein binds Coomassie protein stain very poorly relative to other proteins. It is therefore unlikely that the effects of GARP2 on PDE6 activity reported in this paper could be ascribed to a contaminating protein in our purified GARP2.

The 17-kDa Prenyl-binding Protein (PrBP/-δ) Releases PDE6, but Not GARP2, from ROS Membranes—The 17-kDa prenyl-binding protein (PrBP/-δ), originally described as the δ-subunit of PDE6 (33), is able to solubilize membrane-associated rod PDE6 in vitro (23, 34) by binding to the hydrophobic prenyl groups attached to the C termini of the PDE6 catalytic subunits (35). Because hydrophobic interactions may stabilize GARP2-PDE6 interactions (see previous section), we wondered whether PrBP/-δ binding to PDE6 would solubilize the enzyme as a complex with GARP2 or, alternatively, compete with GARP2 for binding to a hydrophobic region on PDE6. Fig. 3 shows an experiment in which increasing amounts of PrBP/-δ were added to ROS membranes (containing bound PDE6 and GARP2) and the solubilization of PDE6 monitored by centrifugal separation of bound and soluble PDE6. Although PDE6 catalytic and Py-subunits were released from ROS membranes by PrBP/-δ in a concentration-dependent manner, GARP2 remained completely associated with ROS membranes (Fig. 3).

The ability of PrBP/-δ to disrupt GARP2-PDE6 interactions was not restricted to PDE6 associated with ROS membranes. If PDE6 and GARP2 were first released from ROS membranes by hypotonic extraction and then PrBP/-δ was added, some of the GARP2 that normally co-migrated with PDE6 and GARP2 in a gel filtration chromatography profile was now observed eluting at an apparent molecular mass of ~60 kDa (data not shown). The disruption of GARP2-PDE6 interactions by PrBP/-δ suggests that one site of interaction may be at the hydrophobic isoprenyl groups at the C termini of PDE6 catalytic subunits. It is possible that this same binding interface may be disrupted during hydrophobic interaction chromatography.

Purified, Native GARP2 Suppresses Basal PDE6 Catalytic Activity but Does Not Inhibit Activated PDE6—It has been previously reported (8) that GARP2 potently inhibited PDE6 hydrolytic activity when purified PDE6 was activated by transducin in solution; in contrast, trypsin-activated PDE6 (lacking Py) or nonactivated enzyme (αβγy) were not greatly affected by GARP2. However, Korschen et al. (8) used a recombinant GARP2 fusion protein for these experiments, and unpublished results from the same group have called into question the ability of native GARP2 to inhibit transducin-activated PDE6 (36). Furthermore,
transducin activates PDE6 more effectively when both proteins are associated with the disk membrane compared with activation in solution (37, 38). Therefore, we chose to examine whether native, purified GARP2 exerted an effect on nonactivated or activated PDE6 under more physiological conditions in which PDE6 remains associated with the disk membrane.

As seen in Fig. 4, the addition of purified, native GARP2 to nonactivated PDE6 attached to ROS membranes (which contain endogenous GARP2) inhibited the basal rate of PDE6 activity by 80%. The suppression of PDE6 activity by GARP2 was maximal when an amount of purified GARP2 was added equal to its endogenous level in ROS (as determined by quantitative immunoblot analysis). A similar result was obtained with purified PDE6 that had been extracted from ROS membranes and chromatographically purified (data not shown).

In contrast, no significant effect of GARP2 on either transducin-activated PDE6 (attached to ROS membranes) or trypsin-activated PDE6 was seen (Fig. 4). Even following the addition of a 10-fold excess of purified GARP2 relative to its endogenous concentration in ROS membranes, the PDE6 activity of both transducin- and trypsin-activated PDE6 remained within 20% of its activity in the absence of GARP2. Although the results in Fig. 4 for trypsin-activated PDE6 are in accord with those of Korschen et al. (8), we failed to observe the inhibitory effect of GARP2 on transducin-activated PDE6 that they reported.

To more sensitively test whether GARP2 influences the ability of transducin to activate PDE6, we first supplemented light-exposed ROS membranes with either GARP2 or nothing and then added increasing amounts of GTPγS to persistently activate transducin in a concentration-dependent manner. Fig. 5 shows that, in the presence of GARP2 (at a concentration 2-fold greater than required to maximally suppress PDE6 basal activity), the ability of transducin to activate PDE6 was only slightly impaired; the small decrease in activation at any given GTPγS concentration was not statistically significant. Once sufficient GTPγS was added to activate all of the transducin present (the transducin:PDE6 ratio in bovine ROS being 30:1), adding more GTPγS had no further effect on PDE6 activation in the absence or presence of GARP2.

This result shows that the activity-lowering effect of GARP2 on the nonactivated PDE6 holoenzyme is distinct from the molecular events by which the activated α-subunit of transducin binds to PDE6 and displaces its γ-subunit, thereby causing light activation of PDE6.

Proposed Physiological Role for GARP2 Regulation of PDE6 in Rod Photoreceptors—In this study, we have shown that GARP2 is a high affinity PDE6 regulatory protein capable of suppressing the basal activity of nonactivated PDE6 without with negligible effects on transducin-activated PDE6. The exclusive localization of GARP2 to rod outer segments (8, 17) suggests that this protein may regulate rod PDE6 in a way that helps distinguish the rod and cone phototransduction pathways. One feature that differentiates rods from cones is the amplitude of fluctuations in the dark current (dark noise) in the photoreceptor outer segment (10, 11). The low dark noise of rods permits reliable signaling at the single photon level (39), whereas cones require several photons to generate a detectable signal (40).

Because the rates of PDE6 activation/inactivation determine the characteristics of photoreceptor dark noise (12), GARP2 is an attractive candidate for regulating rod PDE6 to lower its spontaneous activation. This study suggests that the binding of GARP2 to nonactivated rod PDE6 will lower its catalytic activity, most likely by enhancing the affinity of Py for the active site of the enzyme. The observed localization of GARP2 to the rim of the disk membrane in ROS (8, 17) may serve as a mechanism to reduce spontaneous PDE6 activation and thereby minimize fluctuations in cGMP concentrations in the vicinity of the cGMP-gated ion channel.

The lack of an effect of GARP2 on transducin-activated PDE6 is also consistent with the need for rod PDE6 to be rapidly and stoichiometrically activated upon binding of activated transducin. The single photon sensitivity of rod photoreceptors would likely be impaired if GARP2 were to reduce the efficiency of PDE6 activation by transducin. In summary, our results support a role for GARP2 in maintaining a very low spontaneous activation of PDE6 without interfering with the efficiency of the visual excitation pathway in rod photoreceptors in response to photic stimuli. Reports that GARP2 is associated with the disk rim protein peripherin (20, 32) leave open the intriguing possibility that GARP2 might preferentially regulate PDE6 in the vicinity of the cGMP-gated channel, where cGMP metabolic flux might be most stringently controlled.

Summary—This work has demonstrated that GARP2 is a novel PDE6 interacting protein that is capable of regulating the basal activity of the PDE6 holoenzyme in rod outer segments. The high affinity with which
it binds nonactivated PDE6 suppresses catalytic activity without adversely affecting the ability of transducin to activate PDE6. This novel regulatory mechanism may be of fundamental importance in establishing the high signal-to-noise ratio needed for single photon detection in rod photoreceptors. Future studies will be directed toward determining the molecular mechanism of GARP2 interaction with the catalytic and/or inhibitory subunits of dark-adapted and light-activated PDE6.

Acknowledgments—We thank Dr. U. Benjamin Kaupf (Institut für Biologische Informationsverarbeitung Forschungszentrum, Jülich, Germany) for intellectual contributions and for sharing results prior to publication and Suzanne Matte for technical assistance.

REFERENCES

1. Rodieck, R. W. (1998) The First Steps in Seeing. Sinauer Associates, Sunderland, MA
2. Burns, M. E., and Baylor, D. A. (2001) Annu. Rev. Neurosci. 24, 779–805
3. Arshavsky, V. Y., Lamb, T. D., and Pugh, E. N., Jr. (2002) Annu. Rev. Physiol. 64, 153–187
4. Zhang, X., and Cote, R. H. (2005) J. Biol. Chem. 280, 18813–18820
5. Calvert, P. D., Govardovskii, V. I., Arshavsky, V. Y., and Makino, C. L. (2002) J. Physiol. 548, 225–237
6. Korschen, H. G., Illing, M., Seifert, R., Sesti, F., Williams, A., Gotzes, S., Colville, C., Müller, F., Dose, A., Godde, M., Molday, L., Kaupp, U. B., and Molday, R. S. (1995) Neuron 15, 627–636
7. Poetsch, A., Molday, L. L., and Molday, R. S. (2003) J. Biol. Chem. 278, 48009–48016
8. Musheritz, R. L., Bunt-Milam, A. H., and Beavo, J. A. (1984) J. Biol. Chem. 259, 8652–8658
9. Burns, M. E., and Baylor, D. A. (2001) Neuron 21, 153–187
10. Cote, R. H., and Brunnock, M. A. (1993) J. Biol. Chem. 268, 1248–1256
11. Rieke, F., and Baylor, D. A. (1996) Neuron 18, 12187–12193
12. Pentia, D. C., Hosier, S., Collupy, R. A., Valetier, B. A., and Cote, R. H. (2005) Methods Mol. Biol. 307, 125–140
13. Naito, A. W., Hosier, S., Terew, J. M., Li, N., Dhingra, A., Vardi, N., Baehr, W., and Cote, R. H. (2005) J. Biol. Chem. 280, 1248–1256
14. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150, 76–85
15. Bownds, D., Gordon-Walker, A., Gaide Huguenin, A. C., and Robinson, W. (1971) J. Gen. Physiol. 58, 225–237
16. Cote, R. H. (2000) Methods Enzymol. 315, 646–672
17. Bownds, D., Molday, L. L., and Molday, R. S. (2001) J. Biol. Chem. 276, 27527–27534
18. Cook, T. A., Ghomashchi, F., Gelb, M. H., Florio, S. K., and Beavo, J. A. (2000) J. Biol. Chem. 275, 27527–27534
19. Dumke, C. L., Arshavsky, V. Y., Calvert, P. D., Bownds, M. D., and Pugh, E. N., Jr. (1994) J. Gen. Physiol. 103, 1071–1098
20. Cote, R. H., and Brunnoch, M. A. (1993) J. Biol. Chem. 268, 17190–17198
21. Musheritz, R. L., Bunt-Milam, A. H., and Beavo, J. A. (1984) J. Biol. Chem. 259, 8652–8658
22. Gallagher, S. (1998) in Current Protocols in Protein Science Unit 10.10 (Coligan, J. E., Dunn, B. M., Ploegh, H. L., Speicher, D. W., and Wingfield, P. T., eds) John Wiley & Sons, Inc., New York
23. Batta-Safferling, R., Abacar, H. K., Korschen, H. G., Triaztizian, C., Stoldt, M., Buday, I., Willbold, D., Schwalbe, H., Klein-Seetharaman, J., and Kaupp, U. B. (2006) J. Biol. Chem. 281, 1449–1460
24. Gillespie, P. G., Prusti, R. K., Apel, E. D., and Beavo, J. A. (1989) J. Biol. Chem. 264, 12187–12193
25. Arshavsky, V. Y., Lamb, T. D., and Pugh, E. N., Jr. (1994) J. Gen. Physiol. 103, 1071–1098
26. Dumke, C. L., Arshavsky, V. Y., Calvert, P. D., Bownds, M. D., and Pugh, E. N., Jr. (1994) J. Gen. Physiol. 103, 1071–1098
27. Cote, R. H., and Brunnoch, M. A. (1993) J. Biol. Chem. 268, 17190–17198
28. Kellner, R., Wolfrum, U., Bode, C., Hofmann, K. P., and Kaupp, U. B. (1999) Nature 400, 761–766
29. Hayashi, F., Matsuura, I., Kashi, S., Maeda, T., Yamamoto, M., Fujii, Y., Liu, H., Yamazaki, M., Usukura, J., and Yamanaka, A. (2000) J. Biol. Chem. 275, 32958–32965
30. Korschen, H. G., Illing, M., Seifert, R., Sesti, F., Williams, A., Gotzes, S., Colville, C., Müller, F., Dose, A., Godde, M., Molday, L., Kaupp, U. B., and Molday, R. S. (1995) Neuron 15, 627–636
31. Poetsch, A., Molday, L. L., and Molday, R. S. (2001) J. Biol. Chem. 276, 48009–48016
32. Arshavsky, V. Y., Lamb, T. D., and Pugh, E. N., Jr. (1994) J. Gen. Physiol. 103, 1071–1098
33. Dumke, C. L., Arshavsky, V. Y., Calvert, P. D., Bownds, M. D., and Pugh, E. N., Jr. (1994) J. Gen. Physiol. 103, 1071–1098
34. Musheritz, R. L., Bunt-Milam, A. H., and Beavo, J. A. (1984) J. Biol. Chem. 259, 8652–8658
35. Rieke, F., and Baylor, D. A. (1996) Biophys. J. 71, 2553–2572
36. Rieke, F., and Baylor, D. A. (2000) Neuron 26, 181–186
37. Calvert, P. D., Govardovskii, V. I., Arshavsky, V. Y., and Makino, C. L. (2002) J. Gen. Physiol. 119, 129–146
38. Arshavsky, V. Y., Lamb, T. D., and Pugh, E. N., Jr. (1994) J. Gen. Physiol. 103, 1071–1098
39. Rieke, F., and Baylor, D. A. (2000) Neuron 26, 181–186
40. Ilm, V., Bunt-Milam, A. H., and Beavo, J. A. (1996) J. Biol. Chem. 271, 32968–32974
41. Colville, C. A., and Molday, R. S. (1996) J. Biol. Chem. 271, 32968–32974